Amphetamine Stimulant denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny an Amphetamine Stimulant as Not FDA-Approved — and How to Appeal

A "not FDA-approved" denial for an amphetamine-class stimulant is worth examining closely, because most amphetamine stimulants in common clinical use carry FDA approval for ADHD and, in some cases, narcolepsy. This denial type usually points to one of three specific situations: (1) the prescribed indication is off-label (used for a condition not listed in the FDA approval); (2) the specific formulation, strength, or delivery system is not yet FDA-approved even if related products are; or (3) there is a coding or documentation error that caused the claim to be misrouted.

If the use is genuinely off-label, that does not automatically mean it is inappropriate or unappealable — many off-label uses are supported by authoritative clinical practice guidelines and peer-reviewed evidence. Federal external-review law extends to these situations.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review with access to all criteria and documents the plan relied on. If the denial rests on an off-label characterization, your prescriber can submit evidence of recognized off-label use.
• External review (ACA §2719): "Not FDA-approved" and off-label denials are explicitly reviewable by an independent IRO, which must consider peer-reviewed literature and recognized clinical standards — not only the FDA label. File within the window stated in your denial letter (typically around 180 days from the final internal denial).
• Expedited review: Available for urgent clinical situations; plans typically must respond within 72 hours.

## Documentation to Gather

1. FDA-approval status clarification — Your prescriber should confirm in writing whether the prescribed use is on-label or off-label, citing the relevant section of the FDA-approved prescribing information. 2. For on-label use: A letter from the prescriber stating that the indication matches the approved labeling, and requesting that UHC identify the specific basis for the "not FDA-approved" determination so you can address it directly. 3. For off-label use: A prescriber letter explaining the clinical rationale, citing the applicable professional guideline organization that recognizes this use, and attaching or referencing supporting peer-reviewed literature (without asserting specific statistics yourself). 4. Diagnosis confirmation — Records documenting the clinical basis for the prescription. 5. Prior treatment history — Documentation supporting why this medication, in this use, was the appropriate clinical choice.

## Criteria-Mapping Strategy

Request the UHC clinical policy document that classifies this use as not approved. For each criterion, prepare a direct response grounded in the chart and the prescribing label. If the denial reflects a documentation gap rather than a genuine coverage exclusion, state that explicitly and provide corrected information. Misrouted denials are often resolved at the internal-appeal stage.